Logo

CombiMatrix Shares Up 6 Percent on News That EAI Will Deploy Its Flu Array

May 17, 2006

NEW YORK, May 17 (GenomeWeb News) - Shares in CombiMatrix were up 6 percent, or $.13, at $2.29 in mid-afternoon trading after the company said EAI, a subsidiary of Science Applications International Corporation, will deploy its array-based influenza screening technology.

 

As GenomeWeb News reported today, CombiMatrix said the deal "gets our technology into the field and into the hands of people and groups standing watch on US soil," said CMBX's CEO Amit Kumar.

Breaking News
The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.